GHK-Cu peptide claims on TikTok: topical vs. injectable reality

What did @dr.martinlanzas actually say?

The transcript provided from this video is, frankly, incoherent. The words attributed to @dr.martinlanzas read as garbled, machine-generated nonsense, references to paying money, seeing the future, and choosing the future of the future. None of it maps to the caption or hashtags. The written caption, however, makes two distinct claims: topical copper peptides (GHK-Cu) "can work" for skin repair and barrier support, and injected GHK-Cu is something this creator does not recommend, citing weak evidence. Since the caption is the only intelligible content available, this fact-check will evaluate those specific written claims rather than the unusable audio transcript.

Does the science back topical GHK-Cu?

On the topical side, the caption gets more right than wrong. The evidence base is modest but real. GHK-Cu has been studied for wound healing, anti-inflammatory signaling, and collagen synthesis stimulation, and the clinical data, while not robust, supports cautious optimism for topical use.

Pickart and Margolina (2018, Cosmetics) reviewed several decades of GHK-Cu research and found consistent signals for fibroblast activation, antioxidant gene upregulation, and barrier recovery in skin models. Gorouhi and Maibach (2009, Skin Pharmacol Physiol) noted copper peptides outperformed placebo in wrinkle reduction in at least one randomized trial. That is not nothing. What the caption is careful not to claim, and this deserves credit, is that it frames topical GHK-Cu as useful for sensitized or post-procedure skin rather than as a cure for aging or disease. That framing is defensible. The compound does appear to support wound environment signaling without the dramatic claims that often surround it on this platform.

What about injected GHK-Cu?

The caption says injected GHK-Cu is not recommended, and the creator implies the evidence usually cited for injectable use is weak. This is the most important and most accurate claim in the post, and it deserves more explanation than the caption cut off before providing.

The honest answer is that systemic or injectable GHK-Cu lacks the clinical trial infrastructure that would justify its use in humans. Most injectable GHK-Cu data comes from in vitro cell studies or animal models, not randomized controlled trials in people. Dou et al. (2020, Frontiers in Aging Neuroscience) looked at GHK-Cu in neurological contexts using animal data, and while findings were interesting, translating that to human injectable protocols is a significant leap. The peptide has a short half-life in circulation, and whether exogenous systemic administration meaningfully raises tissue levels in the right compartments remains unclear. People are injecting this compound based on theoretical mechanisms, not established human dosing or safety data. The caption is right to wave a red flag here.

What did they get wrong, or right?

The written claims in the caption are largely reasonable and show more restraint than most GHK-Cu content on TikTok. The topical-versus-injected distinction is scientifically sensible. The barrier support framing for topical use is supported by available literature. The skepticism toward injected protocols is warranted and, in this space, somewhat brave to state publicly.

Where the post falls short is in what it does not say. The caption was cut off mid-sentence, leaving out whatever evidence critique was coming. That matters. Audiences following peptide content on TikTok are often being sold injectable GHK-Cu by wellness clinics, and a complete explanation of why the injectable evidence is weak would be genuinely useful. Half a warning is better than none, but it is still half a warning. The post also does not address concentration or formulation issues with topical products, which vary enormously across the market and affect whether a product actually delivers the peptide to where it can act.

What should you actually know?

GHK-Cu is a naturally occurring tripeptide found in human plasma that declines with age. That baseline biology is real. The interesting research is mostly mechanistic and preclinical. For topical use, look for formulations with concentrations in the range studied (typically 1-5%), and understand you are getting a supportive ingredient, not a therapeutic drug. For injected use, the risk-benefit calculation is poor right now because the benefit side of that equation has not been established in controlled human trials. Compounded injectable GHK-Cu is not equivalent to any approved drug and carries sterility and dosing risks that topical application simply does not. If a clinic is recommending injectable GHK-Cu as a longevity or healing protocol, ask them to show you the human trial data. They likely cannot, because it does not yet exist in any meaningful form.